Vator Securities: CREATE Health delivers another exciting tech, ProMIS, which potentially could open up a world of new IP for Immunovia
In our latest research update on Immunovia (link to report ), we presented our forecast of a future diagnostic regimen including a combination of proteomics and genomics-based techs to generate timely and correct diagnosis of cancer. Published in the impactful Nature Communication Biology, (link to article ), Immunovia’s research arm and collaborator CREATE Health demonstrates the powerful combination of the two techs in its novel academic research project, the ProMIS platform. The